TCL Archive Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients December 28, 2012
TCL Archive IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC March 28, 2014